A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate. * Study participant qualified and planning for radical prostatectomy. * At least 1 prostate lesion measurable by MRI \> 0.5 cm within one month of screening. * PSA \> 3 ng/mL within 3 months of screening. * Gleason score 3+4 or higher. * Study participant must be willing to undergo post-treatment imaging by MRI. * ECOG performance status 0 or 1. Exclusion Criteria: * Prior radiotherapy or surgery for prostate cancer. * Prior or ongoing hormonal therapy for prostate cancer. * Prior prostate procedures such as transurethral resection of the prostate, transurethral microwave thermotherapy of the prostate, high-intensity focused ultrasound or minimally invasive BPH procedure. * Study participant unwilling or unable to undergo MRI, including patients with contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc. * Metallic hip implant or any other metallic implant or device that distorts the quality of prostatic MR images. * Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of \> 3 months. * Presence of any metastatic disease. * Prostate volume more than 80 cc at prior MRI imaging. * I-PSS score \>20. * History of prostate infection.